1 |
Yoon MG, Shin DH, Kim JW, et al. Craniospinal irradiation techniques: a dosimetric comparison of proton beams with standard and advanced photonradiotherapy. Int J Radiat Oncol Biol Phys. 81(3), 637-646, 2011
DOI
|
2 |
Schneider U, Kaser-Hotz. Radiation risk estimates after radiotherapy: Application of the organ equivalent dose concept to plateau dose-responserelationships. Radiat Environ Biophys. 44, 235-239, 2005
DOI
|
3 |
Wu Q, Mohan R, Morris M, et al. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas. I: Dosimetric results. Int J Radiat Oncol Biol Phys. 56(2), 573- 585, 2003
|
4 |
Murthy K, Shukeili K, Kumar S, et al. Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT. Biomed Imaging Interv J. 6(3),e29, 2010
|
5 |
Schneider U, Lomax A, Timmermann B. Second cancers in children treated withmodern radiotherapy techniques. Radiother Oncol. 89(2), 135-140, 2008
DOI
|
6 |
Verellen D, Vanhavere F. Risk assessment of radiation induced malignancies based on whole-body dose equivalent estimates for IMRT in the head and neck region. Radiother Oncol. 53, 199-203, 1999
DOI
|
7 |
Hall EJ, Wuu C. Radiation-induced second cancers: The impact of 3D-CRT andIMRT. Int J Radiat Oncol Biol Phys. 56, 83-88, 2003
DOI
|
8 |
Kry SF, Salehpour M, Followill DS, et al. The calculated risk of fatal secondarymalignancies from intensity-modulated radiation therapy. Int J Radiat Oncol BiolPhys. 62, 1195-1203, 2005
DOI
|
9 |
Kry SF, Salehpour M, Followill DS, et al. Out-of-field photon and neutron doseequivalents from step-and-shoot intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 62, 1195-1203, 2005
DOI
|
10 |
Fontenot J. D, Lee A. K, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stageprostate cancer. Int J Radiat Oncol Biol Phys. 74, 616-622, 2007
|
11 |
Hall E. J, Intensity modulated radiation therapy, protons and the risk of secondcancers. Int J Radiat Oncol Biol Phys. 65(1), 1-7, 2006
DOI
|
12 |
Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys. 38, 667-672, 1997
DOI
|
13 |
Donovan EM, James H, Bonora M, et al. Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. Med Phys. 39(10), 5814-5824, 2012
DOI
|
14 |
Schneider U, Walsh L. Cancer risk estimates from the combined JapaneseA-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys. 47(2), 253-263, 2008
DOI
|
15 |
Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958- 1998. Radiat Res. 168, 1-64, 2007
DOI
|
16 |
Preston DL, Pierce DA, Shimizu Y, et al. Effects of recent changes in Atomicbomb survivor dosimetry on cancer mortality risk estimated. Radiat Res. 162,377-389, 2004
DOI
|
17 |
Walsh L, Ruhm W, Kellerer AM. Cancer risk estimates for X-rays with regard to organ specific doses, part I: all solid cancers combined. Radiat Environ Biophys. 43, 145-151, 2004
DOI
|
18 |
Walsh L, Ruhm W, Kellerer AM. Cancer risk estimates for X-rays with regard to organ specific doses, part II: site specific solid cancers. Radiat Environ Biophys. 43, 225-231, 2004
DOI
|
19 |
Schneider U, Zwahlen D, Ross D, et al. Estimation of radiation-inducedcancer from three-dimensional dose distributions: Concept of organ equivalent dose. Int J Radiat Oncol Biol Phys. 61(5), 1510-1515, 2005
DOI
|